Last reviewed · How we verify
Clotrimazole vaginal tablet
At a glance
| Generic name | Clotrimazole vaginal tablet |
|---|---|
| Also known as | Canesten |
| Sponsor | Peking University Shenzhen Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of Lactobacillus in Adjuvant Treatment of RVVC (PHASE4)
- Efficacy and Safety of Clotrimazole+Lactulose Vaginal Suppositories Vs. Clotrimazole Monotherapy in Adult Women with Candidal Vaginitis/Vulvovaginitis (PHASE2, PHASE3)
- Screen-and-treat Strategy for Vaginal Flora Abnormalities in Pregnant Women at High Risk of Preterm Birth (PHASE4)
- A Protocol for the Role of Fractional CO2 Laser in Consolidation Treatment of Recurrent Vulvovaginal Candidiasis (NA)
- Efficacy, Safety LactiSal 1% Gel, LactSal 50 mg, Clotrimazole 100 mg Tablet in Treatment Vulvovaginal Candidiasis (PHASE3)
- Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis (PHASE4)
- Comparative Efficacy Study of 10 mg Dequalinium Chloride (Fluomizin) in the Treatment of Vulvovaginal Candidiasis (PHASE4)
- Comparative Efficacy of Ovule vs Tablet (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clotrimazole vaginal tablet CI brief — competitive landscape report
- Clotrimazole vaginal tablet updates RSS · CI watch RSS
- Peking University Shenzhen Hospital portfolio CI